May 13, 2020 / 2:28 PM / 18 days ago

BRIEF-Ascletis Pharma Says Gets IND Approval From NMPA For Category 1 Drug ASC41 For Clinical Trials

May 13 (Reuters) - Ascletis Pharma Inc:

* GETS IND APPROVAL FROM NMPA FOR CATEGORY 1 DRUG ASC41 FOR CLINICAL TRIALS

* HAS 2 ADDITIONAL DRUG CANDIDATES IN NON-ALCOHOLIC STEATOHEPATITIS PIPELINE: ASC40 IN PHASE II CLINICAL TRIAL & PRE-IND CANDIDATE

* NMPA NOD FOR ASC41 CLINICAL TRIALS OF NON-ALCOHOLIC STEATOHEPATITIS INDICATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below